Clinical trial
A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT01381861 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2011
- Completion date
- December 31, 2013
- Enrollment
- 23 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube carcinoma, primary peritoneal carcinoma, recurrent ovarian cancer